A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Summary

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Lupus Nephritis
• Primary Membranous Nephropathy

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Nkarta, Inc.

Last updated on ClinicalTrials.gov

June 4, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites